Introduction {#sec1-1}
============

Diabetic foot infection is a serious complication of diabetes mellitus that can cause morbidity and disability. It is costly to treat and can be life-threatening, leading to lower limb amputation, and may cause systemic infection and septicemia if not treated properly \[[@ref1]\], \[[@ref2]\].

International reports indicate that 25-50% of diabetic patients are subject to amputations due to infections. In the United States, diabetic foot infections are associated with a higher annual rate of referral and hospital admission \[[@ref3]\], \[[@ref4]\].

Reports highlight the negative impact of diabetic foot infections on patients' lives. Diabetic foot infections develop due to the impact of diabetes mellitus on the peripheral nervous system, leading to the motor, sensory, and autonomic neuropathy that cause stress shear, foot deformity, dryness, and peripheral arterial atherosclerosis \[[@ref5]\]. All these factors lead to foot ulcers due to minor trauma. Treatment of diabetic foot ulcers plays a crucial role in preventing infection, but recurrent ulceration and infection can occur. The management of diabetic foot infection varies according to the classification and bone involvement. However, outcomes generally depend on local wound care, surgical debridement, dressing changes, and pharmacological treatment \[[@ref6]\].

Initiating successful management includes an evaluation of the patient's medical history and health status, maintenance of microcirculation, wound depth, and infectious pathogens. In cases of mild wound infection, an inspection of wound depth, abscess drainage, evaluation of microcirculation, and culture sensitivity tests are important measures to choose the proper antibiotic treatment and avoid infection of adjacent tissue \[[@ref7]\], \[[@ref8]\]. Moderate and severe diabetic foot infections require more aggressive surgical wound debridement and drainage of abscesses with minor or major amputations in certain cases in addition to long regimens of antibiotic therapy \[[@ref9]\], \[[@ref10]\].

The proper choice of antibiotics is of great value to cover all the microorganisms involved. The antibiotics should be active against S. aureus and streptococci species that are frequently isolated \[[@ref11]\]. Different guidelines are available for antibiotic selection with no fixed routes, duration, and/or superiority of certain regimens. However, each protocol depends on the severity of infection, isolated microorganisms, and history of previous antibiotic treatment \[[@ref12]\], \[[@ref13]\], \[[@ref14]\].

The current study aimed to evaluate surgical wound management and antibiotic treatment according to the case severity of diabetic foot infections.

Methods {#sec1-2}
=======

We conducted a retrospective clinical study to evaluate the surgical and antibiotic treatment of patients who presented at an orthopaedic consultation clinic from October 2015 to November 2016 with diabetic foot infections of mild and moderate severity according to the IDSA classification ([Table 1](#T1){ref-type="table"}) \[[@ref2]\].

###### 

Diabetic foot infection severity according to IDSA classification

  Clinical description                                                                                                                                                                                                                                           Severity
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------
  Manifestations of inflammation (purulence or erythema, pain, tenderness, warmth, or induration); any cellulitis or erythema extends ≤ 2 cm around the ulcer, limited to skin or superficial subcutaneous tissues; no local complications or systemic illness   Mild
  Infection in a patient who is systemically well and metabolically stable but has ≥ 2 cm; lymphangitis; spread beneath fascia; deep tissue abscess; gangrene; muscle, tendon, joint, or bone involvement                                                        Moderate
  Infection in a patient with systemic toxicity or metabolic instability.                                                                                                                                                                                        Sever

Patients {#sec2-1}
--------

A total of 60 patients were involved in the current study. Their clinical data were recorded, including general information, history of diabetes mellitus, history of diabetic foot infection, history of previous amputation, current antibiotic therapy, and medications.

Examination of the patients included general examination, vital signs, local examination of both feet including neurovascular assessment, and examination of the infected area(s). The patients underwent serological investigations, including random blood sugar, PCV, WBC, C-reactive protein, and ESR. Imaging studies included X-rays of the infected foot with AP and lateral views ([Table 2](#T2){ref-type="table"}).

###### 

Patient's clinical data

  Criteria                                                                        All patients n = 58
  ------------------------------------------------------------------------------- --------------------------------------
  Sex ratio female\\male                                                          22\\36
  Age mean ± SD                                                                   61.5 ± 10.5
  Site of infection                                                               Toes = 30 (58)
                                                                                  Heel = 6 (58)
                                                                                  Other site = 10 (58)
                                                                                  Mixed (more than one site) = 12 (58)
  Patients with osteomyelitis                                                     20 patients (58)
  History of the previous infection                                               46 (58)
  History of amputation                                                           18 (58)
  Patients need partial or complete toe (s) amputation during wound debridement   16 (58)

Doppler studies of both lower limbs were performed to assess circulation. We then consulted an endocrinologist to control the patients' blood sugar and a vascular surgeon to evaluate their peripheral circulation.

Exclusion criteria were (1) severe types of infection according to the IDSA classification, (2) severe ischemia with gangrenous lesions, and (3) diabetic foot ulcers with no signs of infection.

Treatments {#sec2-2}
----------

### Local wound care {#sec3-1}

We started with wound debridement under local anaesthesia and drainage of abscesses (after obtaining wound swabs for culture and sensitivity testing). Some wounds required limited surgical resection of parts of the toe or toes followed by irrigation with normal saline and dressing with gauze soaked in 2% iodine solution. According to the severity, the dressings were changed 1-2 times a day. The patients' wounds were followed-up every 5 days, then every 10-14 days for 3 months after initial improvement.

### Antibiotic treatment {#sec3-2}

Empirical antibiotic treatment was as follows:

Group 1. For mild diabetic foot infections according to the IDSA, the patients in regimen A received 1 dose of oral amoxicillin/clavulanate every 12 hours + 1 dose of metronidazole every 8 hours for 10-14 days ([Figure 1](#F1){ref-type="fig"}). The patients in regimen B who were allergic to penicillin or already on penicillin without a response were administered 1 dose of clindamycin every 6 hours + one dose of metronidazole every 8 hours for 10-14 days.

![Study design diagram](OAMJMS-7-1499-g001){#F1}

Group 2. For the patients with moderate diabetic foot infection with or without osteomyelitis, those in regimen A received intravenous ampicillin/cloxacillin + metronidazole orally for 5 days and then either repeated this course if the response was inadequate or changed to an oral regimen similar to group 1 regimen A for not less than 6 weeks. The patients in regimen B who were allergic to penicillin or already on penicillin without a response received intravenous lincomycin + oral metronidazole for 5 days and then either repeated this course if the response was inadequate or changed to an oral regimen according to group 1 regimen B for not less than 6 weeks ([Figure 1](#F1){ref-type="fig"}).

### Drugs {#sec3-3}

\(1\) Amoxicillin/clavulanate, 1000 mg oral tablets (CoAmox Acino, Acino, Zurich, Switzerland).(2) Metronidazole, 500 mg oral tablets (Flagyl, Sanofi-Aventis, Gentilly, France).(3) Clindamycin hydrochloride, 300 mg oral capsules (Lanacin, Al-Mutahida, Amman, Jordan).(4) Ampicillin + cloxacillin, 250 mg/250 mg intravenous injection (LDP Torlan, Barcelona, Spain).(5) Lincomycin hydrochloride, 600 mg intravenous injection every 8 hours (Lincocin, Pfizer, Puurs, Belgium).

Outcome assessment {#sec2-3}
------------------

We classified the patients according to their responses to management during the follow-up periods, which were every 5 days in the acute stage (for the first 3 weeks), then every 10-14 days for the next 3 months.

The responses according to Lipsky (1997) \[[@ref15]\] were (1) cure: all signs and symptoms of inflammation, pus, and osteomyelitis had disappeared, and the wound had begun to heal; (2) improvement: incomplete abatement of the signs and symptoms of infection; and (3) failure: no improvements.

Secondary outcomes involved adverse reactions to the antibiotic regimens.

Results {#sec1-3}
=======

Overall, 58 patients were included in this study after the exclusion of two cases due to the development of adverse reactions to the medications. Among the patients in group 1 who received regimen A, eight were cured (80%) and 2 (20%) failed to respond and shifted to regimen B in group 1, while 6 patients in group 1 who received regimen B (100%) were cured after a treatment period of 10-14 days ([Table 3](#T3){ref-type="table"}).

###### 

Clinical outcome of 16patients included in group1 (mild diabetic foot infection)

  Group 1 No.16   Patients outcome of both regimen A, B of treatment   Regimen A No .10   Regimen B No.6
  --------------- ---------------------------------------------------- ------------------ ----------------
  Cure            14 (16) 87.5%                                        8 (10) 80%         100%
  Improved        0                                                    0                  0
  Failed          2 (16) 12.5% shifted to G2                           2 (10) 20%         0

A total of 42 patients were included in group 2, and 26 received regimen A; 16 patients were cured, 3 improved, and 7 failed to respond at the end of the treatment period ([Table 4](#T4){ref-type="table"}).

###### 

Total clinical outcome of 42patients included in-group2 at the end of the treatment period (moderate diabetic foot infection)

  Group 2 Patients No.42   Total clinical outcome of both regimen   Regimen A No.26   Regimen B No.16
  ------------------------ ---------------------------------------- ----------------- -----------------
  Cure                     27 (42) 64.28%                           16 (26) 61.5%     11 (16) 68.75%
  Improved                 5 (42) 11.9%                             3 (26) 11.53%     2 (16) 12.5%
  Failed                   10 (42) 23.8%                            7 (26) 26.9%      3 (16) 18.75%

A total of 16 patients in group 2 received regimen B; 11 were cured, 2 improved, and 3 failed to respond at the end of the treatment period (Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}).

###### 

Clinical outcome of group 2 about duration of parenteral injection

  Group 2 Patients No.42   6 weeks regimen including 5 days of injectable treatment   6 weeks regimen including 10 days of injectable treatment   6 weeks regimen including 15 days of injectable treatment                            
  ------------------------ ---------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------- ------------ ----------- ----------
  Cure                     12 (28.57%)                                                4 (9.5%)                                                    4 (9.5%)                                                    6 (14.28%)   0           1 (2.3%)
  Improved                 2 (4.7%)                                                   1 (2.3%)                                                    1 (2.3%)                                                    1 (2.3%)     0           0
  Failed                   1 (2.3%)                                                   1 (2.3%)                                                    1 (2.3%)                                                    0            5 (11.9%)   2 (4.7%)

Secondary outcomes included diarrhoea and skin rash, which developed in 2 patients in group 1 and required changes in treatment and exclusion. Most of the patients well tolerated the antibiotics with minor gastric upset that was treated with antacids.

The results of culture and sensitivity tests in 21 patients were mainly Gram-positive species including staphylococci and streptococci. Most were mixed infections; three patients had E. coli, and one had pseudomonas.

Two patients in group 1 regimen A were switched to group 1 regimen B, and both were cured after 14 days of treatment.

The follow-up period continued for 3 months, including local wound care every 10-14 days (after completion of the antibiotic regimens). As a result, (1) there was no recurrence in the cured cases; (2) 3 of the improved cases were cured at the end of the follow-up period, while 2 cases had to repeat the antibiotic regime; and (3) all of the failed cases resulted in amputation.

Discussion {#sec1-4}
==========

Diabetes mellitus is a systemic disease associated with complications that lead to morbidity. One of these complications is diabetic foot infection that may end with morbidity and mortality.

Many treatment guidelines lead to good clinical outcomes. All aim for higher success rates with less risk of amputations.

The current study's goal was to evaluate surgical and pharmacological therapy for diabetic foot infection of mild and moderate severity in outpatients both with and without osteomyelitis. We choose the IDSA classification, as it was more applicable to and representative of our cases and easily performed. Severe cases were excluded due to the necessity for hospitalisation. The included patients were treated in an orthopaedic consultation clinic using thorough wound debridement and dressing soaked in iodine to ensure protection from contamination. Wound debridement and care are very important as the initial step in diabetic foot infection treatment to remove all necrotic tissue and drain abscesses. Frequent daily dressing is a very effective method for controlling infection and reducing the need for long-term antibiotic administration \[[@ref16]\], \[[@ref17]\], \[[@ref18]\].

In this study, we used inexpensive antibiotics, have been widely used for many years, have well-known side effects, and can be administered to outpatients. Also, they include all common types of causative microorganisms of diabetic foot infections. Using these types of antibiotics leads to a success rate, similar to the results of recent studies including new generations of antibiotics that are expensive, require hospital admission, and necessitate similar treatment periods \[[@ref19]\], \[[@ref20]\], \[[@ref21]\].

The cure rate in group 1 was 87.5%, which is acceptable, as the patients had no osteomyelitis and positive responses to the selected empirical antibiotics; there was good coverage of the microorganisms in this wound type with adequate penetration of the infected skin, soft tissue, and bone, in addition to low cost. Our results agree with those of De Vries \[[@ref22]\] in a study that retrospectively evaluated the effectiveness of clindamycin and cephalosporin for the treatment of diabetic foot infection caused by Staphylococcus aureus and Gram-negative organisms, with an 87% success rate.

Metronidazole was administered to both groups as it is well tolerated and provides antimicrobial activity against most anaerobic microorganisms involved in this condition and colitis caused by Clostridium difficile \[[@ref23]\]. This could explain the low frequency of adverse reactions observed during the treatment period; adverse reactions occurred in 2 patients in the group treated with oral clindamycin.

In group 2, the cure rate was 64.28% in both regimes, although 20 patients had osteomyelitis, which can affect the success rate. Nevertheless, 35% of the patients with osteomyelitis were cured and 20% improved during the antibiotic regimen, which lasted for 6 weeks, and none relapsed during the 3-month follow-up period. There was no need for hospitalisation and further costs ([Table 6](#T6){ref-type="table"}).

###### 

Clinical outcome about osteomyelitis involvement

  Group 2 Patients with osteomyelitis No.20   6 weeks regimen including 5 days of injectable treatment   6 weeks regimen including 10 days of injectable treatment   6 weeks regimen including 15 days of injectable treatment   Total                         
  ------------------------------------------- ---------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------- --------- --------- --------- ---------
  Cure                                        2 (10%)                                                    0 (0)                                                       1 (5%)                                                      3 (15%)   0         1 (5%)    7 (35%)
  Improved                                    1 (5%)                                                     1 (5%)                                                      1 (5%)                                                      1 (5%)    0         0         4 (20%)
  Failed                                      1 (5%)                                                     1 (5%)                                                      1 (5%)                                                      0 (0)     4 (20%)   2 (10%)   9 (45%)

The success rate of this study was comparable to many others, such as that of Yadlapalli \[[@ref24]\], which reviewed 58 patients with diabetic foot infections and osteomyelitis treated for 4-6 weeks via intravenous injection of ceftizoxime, ampicillin/sulbactam, cefoxitin, and vancomycin; 79.3% of the patients were healed, although with a different regime of antibiotics. Embil et al., \[[@ref25]\] retrospectively reviewed 325 patients treated with oral antibiotics and oral plus intravenous antibiotics including metronidazole, clindamycin, amoxicillin/clavulanate, ciprofloxacin, and co-trimoxazole. They found a 75.8% remission rate in the oral plus intravenous regimen, although patients with abscesses and acute osteomyelitis were excluded, unlike the current study.

A review of the failed cases found that most were due to uncontrolled blood sugar, despite consultation with the endocrinologist; this was mainly related to the low socioeconomic status of most of the patients in our study.

In conclusion, patients with diabetic foot infections treated with surgical debridement and antibiotic regimens had favourable responses and cure rates during the study period, with lower costs and hospitalisation rates. Local wound care and good local follow-up improved the success rate and reduced the duration of antibiotic treatment. Oral clindamycin and metronidazole have superior success rates in patients with mild diabetic foot infections and intravenous lincomycin and oral metronidazole show a higher cure rate among moderate diabetic foot infection patients with or without osteomyelitis.
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